Withings launches Move ECG in Europe after securing regulatory approval
Withings has launched Move ECG in Europe after announcing it has received the green light from Conformité Européenne (CE). Those in the US will need to wait a bit longer as the company is still waiting for the stamp of approval from the FDA. Withings timed the news to coincide wih IFA 2019, Europe’s largest annual tech gathering.
Essential reading: Top fitness trackers and health gadgets
Originally unveiled at the start of the year at CES 2019 in Los Vegas, Move ECG is the world’s first analog watch capable of recording an electrocardiogram. At the time Withings said the hybrid would be available in Q2. Since then, it seems the company has been stuck in a regulatory nightmare.
The $129 device is one of the most feature packed hybrids out there. It tracks steps, calories, pace, distance, workout routines, sleep, heart rate and even steps climbed.
Its main party trick, though, is the ability to take an ECG measurement, i.e. it allows you to monitor the electric activity of your heart. The gizmo comes with three electrodes, two of which are hidden inside the main body and the third in the stainless steel bezel.
To take a reading, users need to touch and hold both sides of the bezel for around 30 seconds. The info is then synced to the Health Mate app, where they are able to view a detailed graph of heart rate trends and ECG readings.
Those living in Europe can pick up Move ECG on withings.com for $129.95. It’s available in a choice between a black and white watch face, with a variety of wristband colors and materials. The watch should be available for purchase in the US in Q4 this year.
We are hoping to get our hands on a review unit soon, so stay tuned.
Like this article? Subscribe to our monthly newsletter and never miss out!
